TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02881827

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
Study: NCT04172948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus go headset/virtual reality headset
Description: 10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diaphragmatic breathing
Description: 10 minute tutorial on diaphragmatic breathing by a medical professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Description: 10 minute tutorial on diaphragmatic breathing by a medical professional.
Study: NCT00347555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Phosphate
Description: 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG Malaria Vaccine
Description: White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG Malaria Vaccine
Description: White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG Malaria Vaccine
Description: White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG Malaria Vaccine
Description: White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
Study: NCT03017248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine
Study: NCT02881827

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simulation of treatment with the device switched off
Study: NCT03017248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: 0.9% normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine
Study: NCT00366548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent pneumococcal conjugate vaccine with Polysorbate 80

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13 valent pneumococcal conjugate vaccine without Polysorbate 80
Study: NCT02797704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
Study: NCT02881827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs.
Study: NCT00952237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above
Study: NCT02742896

Intervention type: OTHER
Intervention: Erectile dysfunction
Description: The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.~The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm.
Study: NCT03425630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Argicolina
Description: 8 weeks
Study: NCT03157154

Intervention type: OTHER
Intervention: Non interventional study
Description: A query form to all concerned patients by each investigating centre will be send

Intervention type: OTHER
Intervention: Non interventional study
Description: A query form to all concerned patients by each investigating centre will be send
Study: NCT03463941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Dyad Intervention
Description: Phase I: At baseline and at post-intervention, participant height, weight, BMI, fruit and vegetable intake and exercise habits will be measured. Participants will complete surveys and meet each week to learn about nutrition and exercise.~Phase II: Dyads will attend a communication training session to discuss 1) benefits of working with a partner; 2) supportive communication tips; and 3) expected activities for the next 8 weeks, including filling out daily logs. After the training session, the dyads will work together to achieve their health goals. The dyads will return to the church for two check in sessions. At these sessions, participants will turn in their logs, and be weighed. At the end of the intervention, BMI will be reassessed, and surveys and interviews will be completed.
Study: NCT01087411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with fish liver oli capsules
Description: This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with fish liver oli capsules
Description: This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil capsules
Description: This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo oil capsules
Description: This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
Study: NCT02617342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-mediated Intervention
Description: The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
Study: NCT04116684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings Digital Blood Pressure Monitor
Description: This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
Study: NCT03425630

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Argicolina
Description: 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normolip
Description: 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normolip
Description: 8 weeks
Study: NCT03020108

Intervention type: OTHER
Intervention: Blood sample
Description: 2 cc blood samples will be drawn from antecubital vein
Study: NCT04145596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
Study: NCT01862354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse abdominal plan block
Description: Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous wound infusion
Description: In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
Study: NCT02891603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).
Study: NCT03020108

Intervention type: OTHER
Intervention: Blood sample
Description: 2 cc blood samples will be drawn from antecubital vein

Intervention type: OTHER
Intervention: Blood sample
Description: 2 cc blood samples will be drawn from antecubital vein
Study: NCT04327063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of the solution of Saline not exceeding 30 mL of maximal volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume
Study: NCT02028637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TLRs
Description: Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
Study: NCT02476383

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulative therapy
Description: refer to arm descriptions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulative therapy
Description: refer to arm descriptions
Study: NCT01406262

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albiglutide
Description: once weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: oral tablet
Study: NCT02175043

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atrial electrogram and liner ablation
Description: 1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: atrial electrogram and liner ablation
Description: 1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
Study: NCT03484585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Single dose, intake orally, 200 mg
Study: NCT00199108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depocyt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04461236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Supplement
Description: Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
Study: NCT02891603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR taper. SIR levels will be monitored according to program standard operating procedures. Dose modifications of SIR for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
Study: NCT04461236

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03382080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dream School Program
Description: The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
Study: NCT02891603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR taper. SIR levels will be monitored according to program standard operating procedures. Dose modifications of SIR for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR taper. SIR levels will be monitored according to program standard operating procedures. Dose modifications of SIR for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
Study: NCT03382080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dream School Program
Description: The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Support Team
Description: MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~1. Co-location of services and staff working in services~2. One open door to increase accessibility to the services and staff for students~3. Focus on the transition from lower to upper secondary school~4. Close follow-up of students at risk to ensure tailored help to each student~5. Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools.
Study: NCT02497092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Technique of injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Technique of injection
Study: NCT02891603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of TAC taper. TAC levels will be monitored according to program standard operating procedures. Dose modifications of TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of TAC taper. TAC levels will be monitored according to program standard operating procedures. Dose modifications of TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
Study: NCT01781429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVD-523
Description: Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle